This excerpt taken from the XOMA 10-K filed Mar 15, 2005.
4. License Agreements
XOMA has granted more than 30 licenses to biotechnology and pharmaceutical companies for use of patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products.
In 2003 and 2002, XOMA entered into thirteen antibody-related license arrangements. Six of these were cross-license arrangements related to the use of XOMAs bacterial cell expression system technology in phage display. Under the agreements, MorphoSys AG, Biosite Incorporated, Dyax Corp., Cambridge Antibody Technology Limited, BioInvent International AB and Diversa Corporation received licenses to use XOMAs antibody expression technology for developing products using phage display-based antibody libraries. XOMA, in exchange, receives license and other fees as well as access to these companies antibody display libraries, intellectual property and/or services that complement XOMAs existing development capabilities and helps support the Companys own antibody product development pipeline.
These agreements also generally provide releases of the licensee companies and their collaborators from claims under the XOMA patents arising from past activities using the companies respective technologies to the extent they also used XOMAs antibody expression technology. Licensees are generally also allowed to use XOMAs technology in combination with their own technology in future collaborations.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(Continued)